Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance statusJoao V. Alessi, Mark M. Awad, Matthew D. Hellmann et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 58